Serum Progranulin Level Might Differentiate Non-IPF ILD from IPF

Int J Mol Sci. 2023 May 24;24(11):9178. doi: 10.3390/ijms24119178.

Abstract

Diagnosing interstitial lung disease (ILD) can be a challenging process. New biomarkers may support diagnostic decisions. Elevated serum progranulin (PGRN) levels have been reported in liver fibrosis and dermatomyositis-associated acute interstitial pneumonia. Our aim was to assess the role of PGRN in the differential diagnosis of idiopathic pulmonary fibrosis (IPF) and other ILDs. Serum levels of PGRN were measured by enzyme-linked immunosorbent assay in stable IPF (n = 40), non-IPF ILD (n = 48) and healthy controls (n = 17). Patient characteristics, lung function, CO diffusion (DLCO), arterial blood gases, 6-min walk test, laboratory parameters and high-resolution (HR)CT pattern were assessed. In stable IPF, PGRN levels did not differ from healthy controls; however, serum PGRN levels were significantly higher in non-IPF ILD patients compared to healthy subjects and IPF (53.47 ± 15.38 vs. 40.99 ± 5.33 vs. 44.66 ± 7.77 ng/mL respectively; p < 0.01). The HRCT pattern of usual interstitial pneumonia (UIP) was associated with normal PGRN level, while for non-UIP patterns, significantly elevated PGRN level was measured. Elevated serum PGRN levels may be associated with non-IPF ILD, especially non-UIP patterns and might be helpful in cases of unclear radiological patterns in the differentiation between IPF and other ILDs.

Keywords: differential diagnosis; idiopathic pulmonary fibrosis; interstitial lung disease; progranulin; usual interstitial pneumonia.

MeSH terms

  • Diagnosis, Differential
  • Humans
  • Idiopathic Interstitial Pneumonias*
  • Idiopathic Pulmonary Fibrosis* / diagnosis
  • Lung
  • Lung Diseases, Interstitial* / diagnosis
  • Progranulins

Substances

  • Progranulins

Grants and funding

Noémi Eszes was supported by the Hungarian Respiratory Society and Hungarian Respiratory Foundation. Tamás Nagy was supported by the “Development of scientific workshops of medical, health sciences and pharmaceutical educations” (EFOP-3.6.3-VEKOP-16-2017-00009).